# Tofacitinib

## Xeljanz 5mg

##### 臨採

| Title              | Content                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|:-------------------|:------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| TAH Drug Code      | OXELJ                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Indications        | Rheumatoid arthritis: Treatment of moderately- to severely-active rheumatoid arthritis (as monotherapy or in combination with methotrexate or other nonbiologic disease-modifying antirheumatic drugs) in adults who have had an inadequate response to， or are intolerant of， methotrexate.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Dosing             | Rheumatoid arthritis， psoriatic arthritis 5 mg twice daily.Ulcerative colitis induction dose 10 mg twice daily (8-16 weeks)， maintenance dose 5 mg twice daily.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Hepatic Impairment | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Renal Impairment   | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Contraindications  | Hypersensitivity to tofacitinib or any component of the formulation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Adverse Effects    | >10% Infection: Infection (20% to 22%) 1% to 10%: Cardiovascular: Hypertension (2%) Central nervous system: Headache (4%) Gastrointestinal: Diarrhea (4%) Genitourinary: Urinary tract infection (2%) Hepatic: Increased serum ALT (>3 x upper limit of normal; 1%) Infection: Serious infection (2% to 3%) Renal: Increased serum creatinine (<2%) Respiratory: Upper respiratory tract infection (5%)， nasopharyngitis (4%) <1% (Limited to important or life-threatening): Abdominal pain， anemia， BK virus， cellulitis， cryptococcosis， cytomegalovirus disease， decreased heart rate， dehydration， dyspepsia， erythema， esophageal candidiasis， gastritis， hepatotoxicity， herpes zoster， increased creatine kinase， increased serum AST， interstitial pulmonary disease， liver steatosis， lymphocytopenia， malignant neoplasm， musculoskeletal pain， neutropenia， paresthesia， peripheral edema， pneumocystosis， pneumonia， prolongation P-R interval on ECG， pruritus， rhabdomyolysis， sinus congestion， skin carcinoma， skin rash， tendonitis， tuberculosis |
| Pregnancy          | No (limited) human data – animal data suggest low risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Lactation          | No (Limited) Human Data - Potential Toxicity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |

